Inventor · disambiguated record
Marcus Kelly
Also filed as: KELLY MARCUS · KELLY MARCUS P
19 granted patents·3 pending applications·197 citations·filing 2014–2022
94Inventor score
Files withREGENERON PHARMA22
Top patents by PatentIndex Score
22 records- 0198US9302015B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Apr 5, 2016·82 cites·57 claims
- 0296US11511001B2Radiolabeled anti-LAG3 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2020·Granted Nov 29, 2022·3 cites·7 claims
- 0396US10738130B2Bispecific antigen-binding molecules that bind MUC16 and CD3, and compositions thereofREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·50 cites·49 claims
- 0495US11896682B2Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereofREGENERON PHARMA·Filed 2020·Granted Feb 13, 2024·3 cites·47 claims
- 0595US11485793B2Anti-MUC16 antibodies, antibody-drug conjugates, and bispecific antigen-binding molecules that bind MUC16 and CD3, and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·4 cites·44 claims
- 0694US12053534B2Radiolabeled anti-PD-L1 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2021·Granted Aug 6, 2024·2 cites·26 claims
- 0793US10941208B2Anti-MUC16 antibodiesREGENERON PHARMA·Filed 2017·Granted Mar 9, 2021·6 cites·2 claims
- 0893US9475875B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2015·Granted Oct 25, 2016·14 cites·9 claims
- 0991US10905784B2Radiolabeled anti-LAG3 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2018·Granted Feb 2, 2021·9 cites·24 claims
- 1091US10736976B2Radiolabeled anti-PD-L1 antibodies for immuno-PET imagingREGENERON PHARMA·Filed 2017·Granted Aug 11, 2020·7 cites·6 claims
- 1191US10738124B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2018·Granted Aug 11, 2020·3 cites·27 claims
- 1287US9545451B2Anti-PRLR antibodies and methods for killing PRLR-expressing cellsREGENERON PHARMA·Filed 2014·Granted Jan 17, 2017·6 cites·21 claims
- 1384US9688764B2Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodiesREGENERON PHARMA·Filed 2016·Granted Jun 27, 2017·3 cites·47 claims
- 1482US10683354B2Antibody-drug conjugates comprising anti-prolactin receptor (PRLR) antibodies and methods of use thereof to kill PRLR-expressing cellsREGENERON PHARMA·Filed 2018·Granted Jun 16, 2020·1 cites·26 claims
- 1582US10106616B2Antagonist antibodies to human prolactin receptor (PRLR)REGENERON PHARMA·Filed 2017·Granted Oct 23, 2018·2 cites·16 claims
- 1679US10925971B2Methods of treating PRLR positive breast cancerREGENERON PHARMA·Filed 2017·Granted Feb 23, 2021·1 cites·34 claims
- 1775US10047160B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2016·Granted Aug 14, 2018·1 cites·13 claims
- 1873US2023270894A1Radiolabeled anti-lag3 antibodies for immuno-pet imagingREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1972US11608380B2Anti-EGFRvIII antibodies and uses thereofREGENERON PHARMA·Filed 2020·Granted Mar 21, 2023·0 cites·11 claims
- 2067US2020345872A1Radiolabeled anti-pd-l1 antibodies for immuno-pet imagingREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 2160US2024293566A1ANTI-EGFRvIII ANTIBODY DRUG CONJUGATES AND USES THEREOFREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2251US12144864B2Tubulysins and protein-tubulysin conjugatesREGENERON PHARMA·Filed 2019·Granted Nov 19, 2024·0 cites·33 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →